With autism prevalence now reaching 1 in 31 children in the United States according to the latest CDC data, the pressure on ...

Get all latest & breaking news on Chandrayaan 2. Watch videos, top stories and articles on Chandrayaan 2 at moneycontrol.com.

BACKGROUND: Medically tailored meals (MTM) have unanswered implementation questions. Providing MTM for a specific individual, ...

Space agency is targeting Wednesday for the historic journey-its first to the moon in more than half a century.

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

A pre-specified interim analysis showed dual primary endpoint success, with improved PFS and OS versus physician’s-choice chemotherapy in taxane-progressed advanced TNBC. BL-B01D1-307 was a randomized ...

Novo Nordisk’s GLP-1/amylin combo has topped blockbuster semaglutide in a phase 3 Type 2 diabetes trial, though CagriSema still didn't hit the 25% weight loss mark that the Danish pharma had ...

Previously presented at ESMO 2023, 177 Lu-PSMA-617 prolonged radiographic progression-free survival versus change of androgen receptor pathway inhibitor in taxane-naïve patients with mCRPC in PSMAfore ...

With a late-stage miss reported for its prospective social anxiety disorder (SAD) treatment fasedienol, Vistagen’s chances at an FDA approval in the indication are looking slimmer. That said, the ...

Findings showed treatment with tolebrutinib did not significantly delay disability progression compared with placebo. A phase 3 study evaluating tolebrutinib for the treatment of primary progressive ...

- 48-week data show a 64% decrease from baseline in proteinuria in IgA nephropathy, 82% decrease from baseline in proteinuria in primary membranous nephropathy, and stabilization of estimated ...